Celgene opts in on another Agios drug; Amgen teams up with MD Anderson;

@FierceBiotech: $ALNY and $ISIS strengthen RNAi alliance, agree to swap IP. FierceDrugDelivery article | Follow @FierceBiotech

@JohnCFierce: Last night I had to hug a wall to allow a stampede of biotech execs to surround the NY Times' Pollack. Dangerous work here at #JPM15. | Follow @JohnCFierce

> Celgene ($CELG) has exercised its license option on Agios' Pharmaceuticals' ($AGIO) cancer treatment AG-120. The deal leaves Agios with the U.S. rights to the drug and promises up to $120 million in milestone payments. More

> Amgen ($AMGN) is working with the University of Texas' MD Anderson Cancer Center to use its bispecific T cell engager antibody technology against myelodysplastic syndrome. News

> Capricor Therapeutics has received a $1 million investment from CureDuchenne Ventures to research treatments for heart disease associated with Duchenne muscular dystrophy. Release

Medical Device News

@FierceMedDev: Roche snatches up majority share in Foundation Medicine for $1B plus milestones. Report from FierceDiagnostics | Follow @FierceMedDev

@StacyALawrence: ICYMI yesterday: JP Morgan: With $1.5B spent and a new president, NantHealth works to rationalize patient care. Article | Follow @StacyALawrence

> Biodesix bags $12M in Series E financing for blood-based lung cancer Dx. Story

> Roundup: Device companies announce new financing during JP Morgan confab

> Sleep apnea player Inspire Medical targets reimbursement to bolster launch. Article

Pharma News

@FiercePharma: ICYMI: Is once-skeptical J&J coming around on pharma's breakup craze? More | Follow @FiercePharma

@CarlyHFierce: Merck CEO Frazier credits Keytruda success to slim-down strategy. Article | Follow @CarlyHFierce

> Shire's deal for NPS hasn't curbed its M&A appetite. News

> Thanks to hep C pricing war, Gilead, AbbVie both score spots on Prime's coverage list. More

Biotech Research News

> Investigators electrify antibiotic R&D field with claims of a breakthrough. News

> Team takes a new approach to taming neuroinflammation. Article

> Amgen teams with MD Anderson on new BiTE programs for MDS. Story

> Scientists uncover new target for triple-negative breast cancer. Article

> Scripps researchers find a better way to make a nicotine vaccine. Report

Pharma Manufacturing News

> FDA upgrades Fresenius sterile plant once cited for insect infestation. Story

> AmerisourceBergen moving into vet drug distribution with $2.5B deal for MWI. News

> Group wants FDA to include Indian regulators on plant visits. More

> FDA stops import of Lilly's Cialis from Australia but Lilly says it doesn't make it there. Story

> AMRI buys more manufacturing capacity with deal for two Aptuit facilities. Article

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.